Posted inClinical Updates Neurology news Specialties
Trehalose in ALS: No Efficacy Shown in the HEALEY ALS Platform Trial
Trehalose was safe but did not slow ALS progression compared to placebo in a large, adaptive phase 2/3 trial.
Posted inClinical Updates news
EBIN Study: Sequencing Targeted Therapy and Immunotherapy in BRAFV600-Mutant Advanced Melanoma
A phase 2 trial found that induction targeted therapy with encorafenib and binimetinib before immune checkpoint inhibitors did not improve progression-free survival versus immune checkpoint inhibitors alone in advanced melanoma with BRAFV600E/K mutations.
Posted inClinical Updates news Rheumatology Specialties
Oral Regimens for Whipple’s Disease: A Non-Inferiority Trial of Doxycycline-Hydroxychloroquine Versus Standard Intravenous Therapy
A German phase 2/3 trial found oral doxycycline-hydroxychloroquine as effective and safe as standard intravenous ceftriaxone followed by oral trimethoprim-sulfamethoxazole for Whipple’s disease, potentially transforming outpatient management.
Relacorilant Plus Nab-Paclitaxel: A New Standard for Platinum-Resistant Ovarian Cancer?
Relacorilant combined with nab-paclitaxel significantly improved progression-free and overall survival in platinum-resistant ovarian cancer, with a favorable safety profile, suggesting a potential new treatment standard.
Posted inClinical Updates news Oncology Specialties
Retifanlimab Plus Carboplatin-Paclitaxel: A New Standard for Advanced Squamous Cell Anal Cancer?
Retifanlimab combined with carboplatin-paclitaxel significantly prolongs progression-free survival in advanced squamous cell anal cancer, offering a promising new first-line standard of care.
Long-term Impact of Anifrolumab on Quality of Life in Systemic Lupus Erythematosus: Insights from the TULIP-LTE Trial
A 4-year phase 3 extension study shows that anifrolumab improves patient-reported outcomes and quality of life in systemic lupus erythematosus, with a favorable safety profile.
Semaglutide for Weight Management in Clozapine-Treated Schizophrenia: Results from the COaST Phase 2 RCT in Australia
Semaglutide significantly reduced body weight without impacting psychotic symptoms or clozapine levels in people with schizophrenia and obesity on clozapine therapy.
Posted inClinical Updates HIV/AIDS news Specialties
Comparative Effectiveness of Dolutegravir/Lamivudine Versus Bictegravir/Emtricitabine/Tenofovir Alafenamide for Maintenance Therapy in HIV: Insights from the PASO-DOBLE Trial
The PASO-DOBLE trial demonstrated non-inferiority of dolutegravir/lamivudine versus bictegravir/FTC/TAF for maintenance in virologically suppressed HIV-1 adults, with similar efficacy and safety over 48 weeks.
Avatrombopag in Pediatric Immune Thrombocytopenia: Evidence from the AVA-PED-301 Phase 3b Trial
The AVA-PED-301 phase 3b trial demonstrates avatrombopag’s efficacy and safety as an oral thrombopoietin receptor agonist for children and adolescents with persistent or chronic immune thrombocytopenia.
Posted inClinical Updates news Oncology Specialties Urology
Cabozantinib Plus Atezolizumab in mCRPC: CONTACT-02 Phase 3 Final Results and Clinical Implications
The CONTACT-02 phase 3 trial shows cabozantinib plus atezolizumab improves progression-free survival but not overall survival in advanced mCRPC post-ARPI, offering a novel non-androgen receptor-based option.
Amycretin: A Novel Unimolecular GLP-1 and Amylin Receptor Agonist for Obesity – Early-Phase Clinical Insights and Broader GLP-1 Drug Development Perspective
Amycretin, a new unimolecular GLP-1 and amylin agonist, demonstrated significant weight loss and acceptable tolerability in a phase 1b/2a study, underscoring its potential as an anti-obesity therapy.
Posted inClinical Updates news Oncology Specialties
Short-Course Radiotherapy Plus Sintilimab and Chemotherapy as Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer: Insights from the SPRING-01 Trial
Adding sintilimab to short-course radiotherapy and chemotherapy significantly increased pathological complete response rates in locally advanced rectal cancer, with manageable safety.
Posted inClinical Updates news Oncology Specialties Urology
Metformin in Prostate Cancer: Revisiting Hopes and Realities After Recent Phase 3 Trials
Recent large RCTs show metformin does not improve survival or reduce metabolic syndrome risk in prostate cancer patients on ADT, though it modestly improves metabolic parameters.
Once-Weekly Insulin Regimens in Type 2 Diabetes: Comparative Efficacy, Safety, and Clinical Implications from COMBINE 3 and QWINT Trials
Once-weekly insulin regimens (IcoSema, efsitora alfa) demonstrate non-inferior glycemic control compared to daily injections in type 2 diabetes, with advantages in hypoglycemia risk, weight, and injection burden.
Posted inClinical Updates Gastroenterology news Specialties
Pre-emptive TIPS vs Glue Obliteration for Acute Fundal Variceal Bleeding in Cirrhosis: Key Insights from the GAVAPROSEC Trial
The GAVAPROSEC trial demonstrates that pre-emptive TIPS significantly reduces 1-year mortality and rebleeding in cirrhotic patients with acute fundal gastric variceal bleeding compared to glue obliteration plus NSBB.
Fenebrutinib in Relapsing Multiple Sclerosis: New Evidence from the FENopta Phase 2 Trial
Fenebrutinib, a selective BTK inhibitor, demonstrated significant reduction in new brain lesions and low relapse rates in relapsing multiple sclerosis, with a favorable safety profile in the FENopta phase 2 trial.
Oveporexton: A Promising Orexin Receptor 2 Agonist for Narcolepsy Type 1 – Results from a Phase 2 Randomized Trial
Oveporexton, an oral orexin receptor 2–selective agonist, demonstrated significant improvements in wakefulness and cataplexy in narcolepsy type 1 patients over 8 weeks, with manageable adverse events.
Comparative Efficacy and Safety of Tolebrutinib in Multiple Sclerosis: Insights from Recent Phase 3 Trials
Tolebrutinib reduced disability progression in nonrelapsing secondary progressive MS but did not surpass teriflunomide in reducing relapse rates in relapsing MS. Safety signals include elevated liver enzymes and minor bleeding risks.
Posted inClinical Updates news Respiratory Specialties
Sotatercept in High-Risk Pulmonary Arterial Hypertension: A Landmark Advance in Patient Outcomes
Sotatercept significantly reduces the risk of death, lung transplantation, or hospitalization in high-risk pulmonary arterial hypertension patients, marking a major advance in the management of this life-threatening disease.
Posted inClinical Updates news Oncology Specialties
Regional Nodal Irradiation After Neoadjuvant Chemotherapy: Is Omission Safe for Breast Cancer Patients with ypN0 Status?
A landmark trial shows that omitting regional nodal irradiation after neoadjuvant chemotherapy in breast cancer patients with ypN0 status does not compromise recurrence or survival outcomes.